Parag Patel, MD
Interventional Cardiology · Safety Harbor, FLNPI 1821241324
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (40.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Angiodynamics, Inc. at 40.9% of the total. 2025 is the largest year on record at $29,999, more than ten times the $2,713 reported in 2019.
Across 412 payments — averaging $131.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$22K
- Medtronic$14K
- Boston Scientific$8K
- Abiomed$2K
- Abbott$1K
- W. L. Gore & Associates, Inc.$929
- plus $6K from 36 others
Across 44 payments — averaging $20,364 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$807K
- M.a. Med Alliance S.A.$46K
- Abbott$21K
- Bard Peripheral Vascular, Inc.$14K
- Medalliance LLC$6K
- C. R. Bard, Inc. & Subsidiaries$2K
- plus $26 from 1 others
What the payments were for
- Consulting fees$4501%
- Speaking & faculty fees$14,93828%
- Travel & lodging$3,5407%
- Food & beverage$13,22224%
- Education$120%
- Gifts$400%
- Other$21,91740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$21,917
- SYMPLICITY G3$12,923
- GENERAL VASCULAR ACCESS$3,750
- Impella$738
- GORE EXCLUDER AAA Endoprosthesis$721
- AVVIGO Guidance System$658
- R2P MISAGO$573
- Cook Medical Peripheral Intervention$340
- ENDURANT IIS$292
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$291
- FLOWTRIEVER CATHETER, S$282
- MitraClip$274
- Farapulse$191
- Xience Sierra Coronary Stent System$177
- RXI CONSUMABLES$161
- Mitra Clip system$160
- Cook Medical Micropuncture$158
- Indigo System$150
- GORE TAG Conformable Thoracic Endoprosthesis$149
- STINGRAY$131
How this compares
$54,119 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 383 | $337,360 |
| XareltoRivaroxaban | 194 | $209,238 |
| BrilintaTicagrelor | 181 | $116,589 |
| JardianceEmpagliflozin | 72 | $76,116 |
| EntrestoSacubitril/Valsartan | 70 | $59,724 |
| Repatha SureclickEvolocumab | 63 | $57,586 |
| MultaqDronedarone Hcl | 12 | $22,901 |
| Repatha SyringeEvolocumab | 30 | $17,226 |
| FarxigaDapagliflozin Propanediol | 21 | $16,301 |
| Ranolazine ErRanolazine | 86 | $11,352 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 46 | $9,060 |
| ClopidogrelClopidogrel Bisulfate | 879 | $8,894 |
| Metoprolol Succinate | 586 | $8,715 |
| Atorvastatin Calcium | 575 | $6,199 |
| Losartan Potassium | 328 | $3,923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $156 | $337,360383 claims |
| Johnson & JohnsonXarelto | $49 | $209,238194 claims |
| AstraZenecaBrilinta, Farxiga | $655 | $132,890202 claims |
| NovartisEntresto | $182 | $59,72470 claims |
| Sanofi-aventis U.S. LLCMultaq | $42 | $22,90112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Safety Harbor
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.